A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-lnduced neuromuscular blockGROUDINE, Scott B; SOTO, Roy; LIEN, Cynthia et al.Anesthesia and analgesia. 2007, Vol 104, Num 3, pp 555-562, issn 0003-2999, 8 p.Article

Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas = Essai phase II et pharmacocinétique de l'aziridinylbenzoquinone [2,5-dioziridinyl-3,6-bis(carboéthoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] dans les gliomes de grade élevéCURT, G. A; KELLEY, J. A; KUFTA, C. V et al.Cancer research (Baltimore). 1983, Vol 43, Num 12, pp 6102-6105, issn 0008-5472Article

An early phase II trial with L-deprenyl for the treatment of neuroleptic-induced ParkinsonismPERENYI, A; BAGDY, G; ARATO, M et al.Pharmacopsychiatria. 1983, Vol 16, Num 5, pp 143-146, issn 0720-4280Article

Differential Roles of Phase I and Phase II Enzymes in 3,4-Methylendioxymethamphetamine-Induced CytotoxicityANTOLINO-LOBO, Irene; MEULENBELT, Jan; NIJMEIJER, Sandra M et al.Drug metabolism and disposition. 2010, Vol 38, Num 7, pp 1105-1112, issn 0090-9556, 8 p.Article

Novel Designs and End Points for Phase II Clinical Trials : Phase II Trials: Designs for the futureADJEI, Alex A; CHRISTIAN, Michaele; IVY, Percy et al.Clinical cancer research (Print). 2009, Vol 15, Num 6, pp 1866-1872, issn 1078-0432, 7 p.Article

A two-stage design for a phase II clinical trial of coenzyme Q10 in ALSLEVY, G; KAUFMANN, P; THOMPSON, J. L. P et al.Neurology. 2006, Vol 66, Num 5, pp 660-663, issn 0028-3878, 4 p.Article

Randomized phase II clinical trialsSIMON, R; WITTES, R. E; ELLENBERG, S. S et al.Cancer treatment reports. 1985, Vol 69, Num 12, pp 1375-1381, issn 0361-5960Article

Clinical drug development: an analysis of phase II trials, 1970-1985MARSONI, S; HOTH, D; SIMON, R et al.Cancer treatment reports. 1987, Vol 71, Num 1, pp 71-80, issn 0361-5960Article

PHASE II STUDY OF ANTINEOPLASTIC AGENTS IN JAPANMAJIMA H.1980; RECENT RESULTS CANCER RES.; DEU; DA. 1980; VOL. 70; PP. 61-65; BIBL. 7 REF.Conference Paper

Reversal of Profound, High-dose Rocuronium-induced Neuromuscular Blockade by Sugammadex at Two Different Time Points : An International, Multicenter, Randomized, Dose finding, Safety Assessor-blinded, Phase II TrialPUHRINGER, Friedrich K; REX, Christopher; SIELENKÄMPER, Andreas W et al.Anesthesiology (Philadelphia). 2008, Vol 109, Num 2, pp 188-197, issn 0003-3022, 10 p.Article

Safety and acceptability of the candidate microbicide Carraguard in Thai women : Findings from a phase II clinical trialKILMARX, Peter H; VAN DE WIJGERT, Janneke H. H. M; SUPAWITKUL, Somsak et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 3, pp 327-334, issn 1525-4135, 8 p.Article

Plans expérimentaux pour l'inclusion de patients dans les essais de phase II = Statisticals designs for phase II trialsKRAMAR, A; POTVIN, D; HILL, C et al.Revue d'épidémiologie et de santé publique. 1996, Vol 44, Num 4, pp 364-371, issn 0398-7620Article

Chemotherapy of diffuse malignant mesothelioma: phase II trials of single-agent 5-fluorouracil and adriamycinHARVEY, V. J; SLEVIN, M. L; PONDER, B. A. J et al.Cancer. 1984, Vol 54, Num 6, pp 961-964, issn 0008-543XArticle

Phase-II clinical trial of 4'-epi-doxorubicin in metastatic solid tumorsKOLARIC, K; POTREBICA, V; CERVEK, J et al.Journal of cancer research and clinical oncology. 1983, Vol 106, Num 2, pp 148-152, issn 0171-5216Article

A phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a upid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypassBENNETT-GUERRERO, Elliott; GROCOTT, Hilary P; LEVY, Jerrold H et al.Anesthesia and analgesia. 2007, Vol 104, Num 2, pp 378-383, issn 0003-2999, 6 p.Article

Setting the bar in phase II trials : The use of historical data for determining Go/No Go decision for definitive phase III testing. CommentaryVICKERS, Andrew J; BALLEN, Vennus; SCHER, Howard I et al.Clinical cancer research. 2007, Vol 13, Num 3, issn 1078-0432, 781-782, 972-976 [8 p.]Article

Bayesian sample size calculations in phase II clinical trials using informative conjugate priorsMAYO, Matthew S; GAJEWSKI, Byron J.Controlled clinical trials. 2004, Vol 25, Num 2, pp 157-167, issn 0197-2456, 11 p.Article

Phase II study of rDNA human alpha-2 interferon in multiple myelomaWAGSTAFF, J; LOYNDS, P; SCARFFE, J. H et al.Cancer treatment reports. 1985, Vol 69, Num 5, pp 495-498, issn 0361-5960Article

Phase II trial of mitoguazone in patients with refractory germ cell tumorsHOO CHUN; BOSL, G. J.Cancer treatment reports. 1985, Vol 69, Num 4, pp 461-462, issn 0361-5960Article

Phase II trial of 13-cis-retinoic acid in patients with advanced nonseminomatous germ cell tumorsGOLD, E. J; BOSL, G. J; ITRI, L. M et al.Cancer treatment reports. 1984, Vol 68, Num 10, pp 1287-1288, issn 0361-5960Article

Traitement des adénocarcinomes colo-rectaux par l'association 5 fluoro-uracile (5 FU), doxorubicine (ADR), (essai type II) = Treatment of colo-rectal adenocarcinoma with 5 fluoro-uracil (5FU) and doxorubicine (ADR), (phase II trial)ROUGIER, P; DROZ, J. P; AMIEL, J. L et al.Bulletin du cancer. 1984, Vol 71, Num 1, pp 70-71, issn 0007-4551Article

Early clinical trials of mitoxantrone = Premiers essais cliniques de la mitoxantroneBODEY, G. P; VALDIVIESO, M; HWEE-YONG YAP et al.Monograph series of the European Organization for Research on Treatment of Cancer. 1983, Vol 12, pp 103-114, issn 0146-0447Article

Resampling Phase III Data to Assess Phase II Trial Designs and EndpointsSHARMA, Manish R; KARRISON, Theodore G; YUYAN JIN et al.Clinical cancer research (Print). 2012, Vol 18, Num 8, pp 2309-2315, issn 1078-0432, 7 p.Article

Randomized controlled phase II trial of glatiramer acetate in ALSGORDON, P. H; DOORISH, C; GENDELMAN, H. E et al.Neurology. 2006, Vol 66, Num 7, pp 1117-1119, issn 0028-3878, 3 p.Article

Guidelines for assessing the performance of statisticians involved in clinical research in the pharmaceutical industryPHILLIPS, A.Drug information journal. 1999, Vol 33, Num 2, pp 427-433, issn 0092-8615Conference Paper